Phase III Confirmatory Study of DE-089 Ophthalmic Solution in Patients With Dry Eye

NCT01240382 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

332

Enrollment

INDUSTRY

Sponsor class

Conditions

Dry Eye

Interventions

DRUG: 3% DE-089 ophthalmic solution
DRUG: 0.1% sodium hyaluronate ophthalmic solution

Sponsor

Santen Pharmaceutical Co., Ltd.